Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.US-based SuperGen has reported that its lead JAK2 kinase inhibitors prevented cancer cell proliferation in non-clinical models.
Subscribe to our email newsletter
Testing of the lead candidates in treated leukemia cell cultures indicated that the JAK2 kinase inhibitors were active against both wild-type and mutant JAK2 kinase activity and caused potent inhibition of cancer cell proliferation.
Gregory Berk, chief medical officer of SuperGen, said: “The in vitro inhibition of cancer cell proliferation by our lead JAK2 kinase inhibitors demonstrates the promise that this program holds to treat both hematological cancers and solid tumors.”